Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study

Simple item page
dc.conference.dateSEP 16-21, 2021
dc.conference.titleCongress of the European-Society-for-Medical-Oncology (ESMO)
dc.contributor.authorLeighl, N. B.
dc.contributor.authorShu, C. A.
dc.contributor.authorMinchom, A.
dc.contributor.authorFelip, E.
dc.contributor.authorCousin, S.
dc.contributor.authorCho, B. C.
dc.contributor.authorPark, K.
dc.contributor.authorHan, J-Y.
dc.contributor.authorBoyer, M.
dc.contributor.authorLee, C. K.
dc.contributor.authorMoreno Garcia, V.
dc.contributor.authorTomasini, P.
dc.contributor.authorViteri, S.
dc.contributor.authorXie, J.
dc.contributor.authorMertz, J.
dc.contributor.authorArtis, E.
dc.contributor.authorSchnepp, R. W.
dc.contributor.authorKnoblauch, R. E.
dc.contributor.authorThayu, M.
dc.contributor.authorTrigo Perez, J. M.
dc.contributor.authoraffiliation[Leighl, N. B.] Princess Margaret Canc Ctr, Med, Toronto, ON, Canada
dc.contributor.authoraffiliation[Shu, C. A.] Columbia Univ, Med Ctr, Med, New York, NY USA
dc.contributor.authoraffiliation[Minchom, A.] Royal Marsden Hosp, Inst Canc Res, Drug Dev Unit, Sutton, Surrey, England
dc.contributor.authoraffiliation[Felip, E.] Vall Hebron Univ Hosp, Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Cousin, S.] Inst Bergonie, Oncol Med, Bordeaux, France
dc.contributor.authoraffiliation[Cho, B. C.] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Med Oncol, Seoul, South Korea
dc.contributor.authoraffiliation[Park, K.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Med, Seoul, South Korea
dc.contributor.authoraffiliation[Han, J-Y.] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea
dc.contributor.authoraffiliation[Boyer, M.] Chris OBrien Lifehouse, Med Oncol, Camperdown, NSW, Australia
dc.contributor.authoraffiliation[Lee, C. K.] St George Hosp, Med Oncol, Sydney, NSW, Australia
dc.contributor.authoraffiliation[Moreno Garcia, V.] Hosp Univ Fdn Jimenez Diaz, Early Phase Clin Trials Unit, START Madrid FJD, Madrid, Spain
dc.contributor.authoraffiliation[Tomasini, P.] Aix Marseille Univ, CNRS, Multidisciplinary Oncol & Therapeut Innovat, APHM,CRCM,Hop Nord, Marseille, France
dc.contributor.authoraffiliation[Viteri, S.] Hosp Univ Dexeus, Inst Oncol Dr Rosell, Oncol, Grp Quironsalud, Barcelona, Spain
dc.contributor.authoraffiliation[Xie, J.] Janssen R&D, Clin Biostat, Spring House, PA USA
dc.contributor.authoraffiliation[Mertz, J.] Janssen R&D, Oncol, Spring House, PA USA
dc.contributor.authoraffiliation[Artis, E.] Janssen R&D, Oncol, Spring House, PA USA
dc.contributor.authoraffiliation[Schnepp, R. W.] Janssen R&D, Oncol, Spring House, PA USA
dc.contributor.authoraffiliation[Knoblauch, R. E.] Janssen R&D, Oncol, Spring House, PA USA
dc.contributor.authoraffiliation[Thayu, M.] Janssen R&D, Oncol, Spring House, PA USA
dc.contributor.authoraffiliation[Trigo Perez, J. M.] Hosp Univ Virgen Victoria & Reg, Med Oncol, IBIMA, Malaga, Spain
dc.contributor.funderJanssen
dc.date.accessioned2025-01-07T15:10:43Z
dc.date.available2025-01-07T15:10:43Z
dc.date.issued2021-09-21
dc.identifier.doi10.1016/j.annonc.2021.08.1797
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.annonc.2021.08.1797
dc.identifier.urihttps://hdl.handle.net/10668/26937
dc.identifier.wosID700527702211
dc.issue.number5
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.page.numberS951-S952
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleAmivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen de la Victoria
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía